Sage Therapeutics, Inc. (SAGE) Given a $82.00 Price Target by SunTrust Banks, Inc. Analysts

SunTrust Banks, Inc. set a $82.00 target price on Sage Therapeutics, Inc. (NASDAQ:SAGE) in a research report released on Thursday, October 19th. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on SAGE. J P Morgan Chase & Co cut their target price on Sage Therapeutics from $99.00 to $85.00 and set an overweight rating on the stock in a research note on Tuesday, September 12th. Canaccord Genuity cut their target price on Sage Therapeutics from $110.00 to $81.00 and set a buy rating on the stock in a research note on Tuesday, September 12th. Cowen and Company cut their price objective on shares of Sage Therapeutics from $100.00 to $90.00 and set an outperform rating on the stock in a research note on Tuesday, September 12th. Stifel Nicolaus assumed coverage on shares of Sage Therapeutics in a research note on Wednesday, August 9th. They set a buy rating and a $104.00 price objective on the stock. Finally, BidaskClub cut shares of Sage Therapeutics from a buy rating to a hold rating in a research note on Wednesday, August 23rd. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $86.50.

Shares of Sage Therapeutics (NASDAQ:SAGE) opened at 64.19 on Thursday. Sage Therapeutics has a 1-year low of $38.30 and a 1-year high of $90.80. The firm’s market cap is $2.40 billion. The stock has a 50 day moving average of $64.92 and a 200-day moving average of $73.79.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same quarter in the prior year, the company posted ($1.08) earnings per share. Equities analysts anticipate that Sage Therapeutics will post ($7.40) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/29/sage-therapeutics-inc-sage-given-a-82-00-price-target-by-suntrust-banks-inc-analysts.html.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. increased its stake in Sage Therapeutics by 1.1% in the 1st quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 62 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 138 shares in the last quarter. Keybank National Association OH grew its stake in Sage Therapeutics by 10.6% during the 2nd quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Sage Therapeutics by 19.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 497 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in Sage Therapeutics by 0.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock valued at $4,723,000 after acquiring an additional 552 shares in the last quarter.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply